Anebulo Pharmaceuticals (NASDAQ:ANEB) Releases Earnings Results, Beats Expectations By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) posted its quarterly earnings data on Wednesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Up 4.6 %

Shares of ANEB opened at $2.05 on Friday. The business has a 50-day simple moving average of $2.05 and a two-hundred day simple moving average of $2.35. Anebulo Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $3.61. The stock has a market cap of $53.16 million, a price-to-earnings ratio of -5.54 and a beta of -1.01.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.